Examine This Report on CFSE
Because authorised in 2014, tucidinostat was regarded as a next-line and subsequent therapy for PTCL individuals in China. Scientific trials and preclinical scientific tests in several hematological malignancies and good tumors is in progress.The intention of the current phase IIb research was To guage the efficacy and safety of tucidinostat in ind